Letrozole Tablet, Film Coated
Product Images NDC 42291-374

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 42291-374). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sturctural Formula Of Letrozole (Letrozole Tablets 090289 1)

Chemical structure of Letrozole, showing a central triazole ring connected to two benzene rings each bearing a nitrile (CN) group.*

FDA Label Image

Figure01 (Letrozole Tablets 090289 2)

A Kaplan-Meier survival curve comparing Letrozole and Tamoxifen treatments over 72 months. The graph shows the proportion of patients surviving over time with separate lines for Letrozole (solid) and Tamoxifen (dashed). Patient numbers at risk and event counts are listed below the chart for both treatments.*

FDA Label Image

Figure02 (Letrozole Tablets 090289 3)

A progression-free survival curve comparing Letrozole 2.5 mg and Tamoxifen 20 mg over a period of 60 months. The x-axis represents time in months, and the y-axis represents the proportion of patients progression-free. Two lines depict the progression-free rate for each treatment group over time.*

FDA Label Image

Figure03 (Letrozole Tablets 090289 4)

A survival curve plot depicting the proportion of patients alive over time in months. The graph compares two treatments: Letrozole (solid line) and Tamoxifen (dashed line), showing survival trends up to 60 months.*

FDA Label Image

Figure04 (Letrozole Tablets 090289 5)

A Kaplan-Meier plot illustrating time to progression in days for treatment groups including Letrozole 0.5 mg, Letrozole 2.5 mg, and MA. The y-axis represents the proportion without progression, and the x-axis represents time in days up to 900.*

FDA Label Image

Figure05 (Letrozole Tablets 090289 6)

A Kaplan-Meier survival curve comparing time to progression in days among three treatment groups: Letrozole 0.5 mg, Letrozole 2.5 mg, and AG. The x-axis represents time in days up to 900, and the y-axis shows the proportion of patients without progression, ranging from 0 to 1.*

FDA Label Image

30 (374 30)

Letrozole Tablets, USP 2.5 mg film-coated tablets label by AvKARE. The label indicates the tablet contains 2.5 mg of letrozole and includes FD&C Yellow No. 5 as a color additive. The package contains 30 tablets and is marked for prescription use only. Directions for use and storage instructions are also present on the label.*

FDA Label Image

90 (374 90)

Letrozole 2.5 mg film-coated tablets label by AvKARE. The packaging shows the brand name and strength prominently, with a note that each tablet contains 2.5 mg Letrozole and uses FD&C Yellow No. 5 as a color additive. Contains 90 tablets and is marked Rx Only. Directions and storage instructions are partially visible, along with a barcode and manufacturer details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.